Myosuit Chronic Stroke Protocol (MyoSCSP)

February 16, 2024 updated by: Fondazione Don Carlo Gnocchi Onlus

Valutazione Degli Effetti di un Dispositivo Indossabile Per Arto Inferiore (Myosuit) Sulla accettabilità e Parametri Funzionali di Pazienti Cronici Post-ictus: Studio Pilota.

A stroke is a vascular condition that can suddenly cause the loss of neurological functions. The disability derived from a stroke can imply reduced communication and limited activities of daily living in the long term.

Thus, specifically walking rehabilitation is crucial in order to restore the lower limbs' function and to re-establish the social participation of patients.

Robotics has been demonstrated in being a suitable and effective tool in order to assist and treat post-stroke patients, thanks to its capability to deliver intensive and task-oriented training. Specifically, the exosuits, are a sub-group of robotics devices designed in lighter materials that assist the patients by actively moving the hip, knee or ankle.

Given this framework, the aim of this work is to conduct a pilot study on the usability and perceived effectiveness of a lower-limb exosuit, the Myosuit device, on post-stroke patients. The secondary aims of the study concern the evaluation of the functional performances of the patients both with and without the device and before and after the treatment.

Study Overview

Status

Completed

Detailed Description

A stroke, either ischemic or haemorrhagic, is a vascular condition that can suddenly cause the loss of neurological functions [1]. The disability derived from a stroke can imply reduced communication and limited activities of daily living in the long term. Specifically, reduced mobility and equilibrium, walking asymmetry and spasticity of the impaired limb are the principal factors related to long-term limited physical activity and moderate dependency of the patient on the caregiver [2,3]. A walking deficit can have severe consequences on the energetic cost and the risk of falling, as well as on the participation and personal identity of the person [4].

Moreover, another psychological area that can be affected is self-efficacy, defined as the individual capabilities to take actions for obtaining results. Hence, for a person affected by stroke, self-efficacy is crucial and connected to his/her adaptation to the new condition [5].

For these reasons, walking rehabilitation is essential to recover lower limbs' function, restore self-efficacy and re-establish the social participation of patients [6].

Robotics has been demonstrated in being a suitable and effective tool in order to assist and treat post-stroke patients [7], thanks to its capability to deliver intensive and task-oriented training. One of the most common modalities to classify robotics devices is according to their structure, and the modality to interface with the patients. In these regards, we can distinguish between exoskeletons and end-effector robots, given their characteristics to wear the patient and guide him/her through the distal handle of the mechanical chain, respectively. Moreover, among the exoskeletons, the exosuits are a sub-group of robotics devices designed in lighter materials and that assist the patients by actively moving the hip, knee or ankle.

The lightweight of exosuits makes them suitable both for ecological and therapy-related settings, as well as assistance applications. It is also worth noticing that the absence of a rigid structure requires the patients to have an active component in the walking activity. Previous studies highlighted how these devices can have a supportive capacity during the propulsion phases of gait, assisting the patients throughout the walk [8].

The Myosuit device is a wearable exosuit capable to provide assistance during the walk, sit to stand transition and stair climb [9]. Its assistance is provided with an exo-tendon mechanism. More in detail, online analysis of inertial signals allows to segment the gait phases and to assist at the extension of the knee and hip [9].

Many previous studies show promising results in the deambulation of spinal cord injuries or patients with lower-limb disorders [9,10]. These results were evaluated both in terms of kinematics and the safety of the patients. However, the studies conducted to highlight the urgency for the validation of the device in bigger and different cohorts [9,10].

Given this framework, the aim of this work is to conduct a pilot study on the effects of a lower-limb exosuit, the Myosuit device, on post-stroke patients. The effects of the device will be analysed in terms of usability of the device, self-efficacy, and functional parameters of gait.

Study Type

Interventional

Enrollment (Actual)

10

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Firenze, Italy, 50143
        • IRCCS Fondazione Don Carlo Gnocchi ONLUS

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Clinical stability, evaluated through the administration of the MEWS scale (Modified Early Warning Score);
  • To be able to stand up from a chair without exceeding a trunk angle of 45° to the left or right during the movement;
  • To be able to walk for 10 m without the support of another person but, if necessary, with conventional aids different than knee othesis (e.g. stick, crutch, ankle/foot orthesis). The aid considered should have single-support;
  • Height between 150 cm and 195 cm;
  • Weight between 45 kg and 110 kg;
  • FAC (Functional Ambulation Calssification) ≥3;
  • MAS (Modified Ashworth Scale) ≤2;
  • HADS (Hospital Anxiety and Depression Scale) with normative values (>10/21 for each scale);
  • MoCA (Montreal Cognitive Assessment) (Equivalent scoring > 1 with the Italian correction from Santangelo et al._ 2015);
  • To be able to understand and sign the informed consent.

Exclusion Criteria:

  • Presence of an active (or with effects) neurological or psychiatric pathology occurred before the vascular event;
  • Severe bilateral hearing or sight loss;
  • Functional Reach Test <15.24;
  • Flexion retruction of hip and knee greater than 10° and not reducible;
  • Presence of genu varum or geru valgum greater than 10°;
  • Pregnancy;
  • Previous stroke.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Device Feasibility
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Lower limbs robotic intervention

The intervention administered in this arm is a lower limb robotic intervention using the device Myosuit. The intervention includes:

  • An enrollment (session1), in which a clinical and psychological evaluation is performed for the assessment of the inclusion criteria
  • A baseline evaluation (session2), in which a functional evaluation is performed both with and without the device
  • Training sessions (sessions 3-9), these are the actual training sessions in which walking, sit to stand, balance and stairs climbing tasks are performed with the device on
  • Final evaluation (session 10), in which a final functional, clinical, and psychological assessment is performed

The sessions are performed 3 times per week, with a duration of 45 minutes, with the expection of the assessement ones, session 1, 2 and 10, that have a duration of 1h, 2h and 3h, respectively.

The intervention proposed in this study involves the use of an exosuit for lower limbs, the Myosuit. The selection of the tasks has been done in order to replicate typical activities of daily living in a structured environment, i.e. a rehabilitation hospital.

Specifically, the tasks involve walking, sit to stand, balance and stair climbing.

During the phases of assessment (session 2 and session 10), other devices are be used. Specifically:

  • The Optogait system; for a markerless gait analysis;
  • The Gyko sensor; an inertial sensor that will be used at the beginning of the training for the synchronisation of the signals recorded by the Myosuit and the signal recorded by the Optogait.

Finally, during all the sessions, the Polar heart rate sensor is used to constantly monitor the cardiac frequency of the patients.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Usability of the device
Time Frame: Evaluated at session 10 (after the treatment) at an average of 3 weeks
System Usability Scale (SUS) Range: 0-100, with 100 corresponding to the highest degree of usability
Evaluated at session 10 (after the treatment) at an average of 3 weeks
Self-efficacy
Time Frame: Evaluated at session 10 (after the treatment), at an average of 3 weeks
Stroke Self-Efficacy Questionnaire (SSEQ-10) Range: 0-39; with 39 corresponding to the maximum confidence of the patient in self-efficacy
Evaluated at session 10 (after the treatment), at an average of 3 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Variation of functional status after the treatment
Time Frame: Evaluated at session 1 (before the beginning of the treatment) and at session 10 (after the treatment) without the device
Short Physical Performance Battery (SPPB) Range: 0-12; with 12 corresponding to the best perfromance on balance, walking, and sit-to-stand tasks
Evaluated at session 1 (before the beginning of the treatment) and at session 10 (after the treatment) without the device
Functional assistive direct effect of the device
Time Frame: Evaluated at session 1 (before the beginning of the treatment) with and without the device
Short Physical Performance Battery (SPPB) Range: 0-12; with 12 corresponding to the best perfromance on balance, walking, and sit-to-stand tasks
Evaluated at session 1 (before the beginning of the treatment) with and without the device
Variation of walking capabilities after the treatment
Time Frame: Evaluated at session 1 (before the beginning of the treatment) and at session 10 (after the treatment) without the device

Distance walked during the Two Minutes Walking Test (2minWT), in meters

Range: Not available; higher distances represent better performances on the walking task

Evaluated at session 1 (before the beginning of the treatment) and at session 10 (after the treatment) without the device
Assistive direct effect of the device on walking capabilities
Time Frame: Evaluated at session 1 (before the beginning of the treatment) with and without the device

Distance walked during the Two Minutes Walking Test (2minWT), in meters

Range: Not available; higher distances represent better performances on the walking task

Evaluated at session 1 (before the beginning of the treatment) with and without the device
Variation of walking capabilities after the treatment
Time Frame: Evaluated at session 1 (before the beginning of the treatment) and at session 10 (after the treatment) without the device

Time needed to execute the 10 Meters Walk Test (10mWT), in seconds

Range: Not available; higher durations represent worst performances on the walking task

Evaluated at session 1 (before the beginning of the treatment) and at session 10 (after the treatment) without the device
Assistive direct effect of the device on walking capabilities
Time Frame: Evaluated at session 1 (before the beginning of the treatment) with and without the device

Time needed to execute the 10 Meters Walk Test (10mWT), in seconds

Range: Not available; higher durations represent worst performances on the walking task

Evaluated at session 1 (before the beginning of the treatment) with and without the device
Variation of stair ascending and descending capabilities after the treatment
Time Frame: Evaluated at session 1 (before the beginning of the treatment) and at session 10 (after the treatment) without the device

Time needed to execute the Stair Climb Test (SCT), in seconds

Range: Not available; higher durations represent worst performances on the stair climb task

Evaluated at session 1 (before the beginning of the treatment) and at session 10 (after the treatment) without the device
Assistive direct effect of the device on stair ascending and descending capabilities
Time Frame: Evaluated at session 1 (before the beginning of the treatment) with and without the device

Time needed to execute the Stair Climb Test (SCT), in seconds

Range: Not available; higher durations represent worst performances on the stair climb task

Evaluated at session 1 (before the beginning of the treatment) with and without the device
Variation of gait kinematic after the treatment
Time Frame: Evaluated at session 1 (before the beginning of the treatment) and at session 10 (after the treatment) without the device

Spatio-temporal kinematic parameters extracted from the Optogait system, such as:

  • step length (meters)
  • stride length (meters)
  • stride time (seconds)
  • step time (seconds)
  • swing time (seconds)
  • cadence (steps/minute)
  • velocity (meters/seconds)
Evaluated at session 1 (before the beginning of the treatment) and at session 10 (after the treatment) without the device
Assistive direct effect of the device on gait kinematic
Time Frame: Evaluated at session 1 (before the beginning of the treatment) with and without the device

Spatio-temporal kinematic parameters extracted from the Optogait system, such as:

  • step length (meters)
  • stride length (meters)
  • stride time (seconds)
  • step time (seconds)
  • swing time (seconds)
  • cadence (steps/minute)
  • velocity (meters/seconds)
Evaluated at session 1 (before the beginning of the treatment) with and without the device

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 7, 2022

Primary Completion (Actual)

April 7, 2023

Study Completion (Actual)

October 10, 2023

Study Registration Dates

First Submitted

July 28, 2022

First Submitted That Met QC Criteria

October 11, 2022

First Posted (Actual)

October 13, 2022

Study Record Updates

Last Update Posted (Actual)

February 20, 2024

Last Update Submitted That Met QC Criteria

February 16, 2024

Last Verified

February 1, 2024

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Stroke

Clinical Trials on Lower-limb robotic intervention

Subscribe